Innovative Lutetium Treatment Eliminates Active Prostate Cancer in Advanced Patient at Ziv Medical Center
How 4 Israeli newsrooms covered this story — translated into English and compared side by side.
First reported by Mako · Aug 4, 2026
What happened
A 66-year-old metastatic prostate cancer patient at Ziv Medical Center in Safed achieved complete remission of active disease following Lutetium-177 PSMA therapy, marking a rare and promising response. The treatment delivers targeted radiation to cancer cells and is now accessible to northern Israel residents, reducing travel burdens. Medical staff highlight the therapy's potential to improve outcomes and urge continued cancer screening.
- 01A 66-year-old metastatic prostate cancer patient showed no active disease after Lutetium-177 PSMA treatment.
- 02The therapy targets PSMA proteins on cancer cells, delivering focused radiation and sparing healthy tissue.
- 03Treatment is outpatient, included in Israel's health basket, and for patients resistant to hormonal or chemotherapy.
- 04Ziv Medical Center uses advanced imaging to optimize treatment and monitor patient response.
- 05The new service allows northern Israel patients to access advanced care without traveling to central hospitals.
- 06Doctors stress the importance of regular cancer screening for early detection and better outcomes.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 4 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
